DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Hellmann MD, Rizvi NA, Goldman JW. et al.
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Lancet Oncol 2017;
18: 31
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.